Targeting Tryptophan metabolism pathway as a therapeutic strategy for non-small cell lung cancer Source: International Congress 2019 – Biology of lung cancer Year: 2019
Alteration in clotting system in non-small cell lung cancer patients Source: Eur Respir J 2004; 24: Suppl. 48, 74s Year: 2004
Influence of overexpression of coagulantic and fibrolytic components in tumor tissues on the prognosis of non-small cell lung cancer Source: Annual Congress 2007 - Diagnosis and prognosis in thoracic oncology Year: 2007
Changes of lung function in patients with non-small cell lung cancer tretaed by chemotherapy Source: Eur Respir J 2006; 28: Suppl. 50, 771s Year: 2006
Effect of comorbidity on the prognosis of non-small cell lung cancer Source: Eur Respir J 2006; 28: Suppl. 50, 385s Year: 2006
The impact of neuroendocrine differentiation in the prognosis of non-small cell lung cancer Source: Annual Congress 2012 - Prognosis of lung cancer Year: 2012
Correlation between the activation of coagulation-fibrinolysis system and prognosis of nonsmall cell lung cancer Source: Eur Respir J 2001; 18: Suppl. 33, 231s Year: 2001
Soluble non-invasive markers in non-small cell lung cancer Source: Eur Respir J 2005; 26: Suppl. 49, 459s Year: 2005
Global screening of AKT/PI3K signaling molecules for non-small cell lung cancer and its prognosis Source: Annual Congress 2010 - Prognostic factors for lung cancer Year: 2010
Pulmonary complications of immune checkpoint inhibitors in patients with nonsmall cell lung cancer Source: Eur Respir Rev, 28 (153) 190058; 10.1183/16000617.0058-2019 Year: 2019
The expression of central cell cycle regulators in non-small cell lung cancer has therapy-dependent prognostic impact Source: Annual Congress 2012 - New results in molecular pathology and functional genomics of neoplastic and non-neoplastic lung disease Year: 2012
Ubiquitin-proteasome pathway and NF-κB activity in skeletal muscle of patients with non-small cell lung cancer Source: Eur Respir J 2006; 28: Suppl. 50, 622s Year: 2006
Serum hepcidin and iron are associated with non-small cell lung cancer stage Source: International Congress 2016 – Prognostic variables in lung cancer I Year: 2016
Adenylate cyclase-associated protein 1 is associated with metastasis of non-small cell lung cancer especially in brain metastasis patients and promotes the lung cancer cell proliferation and migration in vitro as well as its growth and metastasis in vivo by the signaling pathways of limk1-cofilin Source: International Congress 2015 – New frontiers in biomedical research on thoracic tumours Year: 2015
CHD4 is associated with poor prognosis of non-small cell lung cancer patients through promoting tumor cell proliferation Source: International Congress 2016 – Prognostic variables in lung cancer I Year: 2016
Is mitochondrial dysfunction a driving mechanism linking COPD to nonsmall cell lung carcinoma? Source: Eur Respir Rev, 26 (146) 170040; 10.1183/16000617.0040-2017 Year: 2017
Role of anlotinib-induced CCL2 decrease in anti-angiogenesis and response prediction for nonsmall cell lung cancer therapy Source: Eur Respir J, 53 (3) 1801562; 10.1183/13993003.01562-2018 Year: 2019
Assessment of lipid peroxidation and antioxidant capacity in pulmonary parenchyma and lung cancer tissue in non-small cell lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 79s Year: 2004
Role of chemokines in resectable non-small cell lung cancer (NSCLC) Source: International Congress 2019 – Biology and prognosis of lung cancer Year: 2019